Cizzle Bio appoints iGenomeDx as the first COLA and CLIA accredited laboratory to launch the CIZ1B blood test

Cizzle Bio shared a post on LinkedIn:

“Announcement: Cizzle Bio, Inc. has appointed iGenomeDx Inc. as the first COLA-accredited and CLIA-certified clinical laboratory to launch the commercial CIZ1B blood test in the U.S.

This non-invasive test aims to detect early-stage lung cancer and is the result of a strong collaboration between Cizzle Biotechnology plc (UK), Cizzle Bio (USA), and iGenomeDX.

We’re proud to share this major milestone in our journey toward improving early cancer detection and outcomes.

Read the full update.”